

SEER Inquiry System - Report  
Produced: 05/20/2024 12:42 AM

## Question 20240002

### References:

#1: Heme & Lymph Manual & DB, 25-26. Published August 2021

#2: 2023 SEER Manual, 234-236. Other Therapy

### Question:

First Course Treatment--Heme & Lymphoid Neoplasms: How should treatment data items be coded for a diagnosis of myelodysplastic syndrome (MDS) and symptomatic anemia treated with Reblozyl (Luspatercept)? See Discussion.

### Discussion:

Example: Patient has a 04/2023 diagnosis of symptomatic anemia not responsive to Retacrit. Further testing includes diagnostic bone marrow biopsy 10/2023 proving MDS with low blasts and SF3B1 mutation, treated with Reblozyl (Luspatercept).

There is no SEER\*Rx listing for Reblozyl or Luspatercept. Per web search, Luspatercept, sold under the brand name Reblozyl, is a medication used for the treatment of anemia in beta thalassemia and myelodysplastic syndromes.

Is this non-cancer directed treatment since it is given to address the anemia rather than the MDS? If cancer-directed treatment, how should it be coded?

### Answer:

Do not code Reblozyl (luspatercept) as treatment. Luspatercept is an ancillary drug approved to treat anemia associated with MDS but not the malignancy.

### Cancer Site Category:

Heme & Lymphoid Neoplasms

### Data Item Category:

First course treatment

### Other Category:

N/A

### Year:

2024